| Biomarker ID | 588 |
| PMID | 21305254 |
| Year | 2011 |
| Biomarker | Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1); |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(SERPINA1):-Interleukin-6 regulation of target genes,HNF3A pathway,Complement and coagulation cascades,p73 transcription factor network,Response to elevated platelet cytosolic calcium Pathways Include(PHB):-Integrated breast cancer pathway,T cell receptor regulation of apoptosis |
| Experiment | Gleason Score 5 Vs Gleason Score 7 |
| Type of Biomarker | Prognostic |
| Cohort | Samples from 16 patients diagnosed with BPH along woth 8 patients with prostate cancer were chosen. 4 had Gleason Score 7 and 4 had Gleason Score 5. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | MALDI-TOF-MS |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ANXA4, APOA1, ATP5B, CKB, DES, ECHS1, FGG, HSPA5, HSPD1, P4HB, PHB, SERPINA1 |